GENSET - GENXY Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Angelo Ferraro who wrote (4)	10/15/1999 8:02:00 AM
From: Angelo Ferraro	Read Replies (1) of 200

worldlyinvestor.com Genset: A Negative Bottom Line One biotech stock that was highly regarded just two years ago was France's Genset (GENXY: Nasdaq ADR). The most distinctive element of Genset's technology portfolio is its high-resolution physical map of the human genome, which includes gene-sequence mutations. Identifying these mutations, also called single nucleotide polymorphisms (SNPs) is a hot area of research, and Genset's SNP program is arguably the most advanced and best-positioned in the industry. Genset has developed a proprietary database that includes more than 50,000 DNA sequences, and the company's most notable discovery is the gene that predisposes men to prostate cancer. However, interest in Genset over the last two years has waned and its stock has lost nearly 67% of its value. Why? Genset isn't generating any real earnings - which, despite the Internet craze, still matters to many on Wall Street. Moreover, Genset's insistence on keeping its knowledge base proprietary has its costs. The company has begun investing more in research to discover its own genes that it can then sell; undoubtedly the right strategy but a painful one in the near-term as profitability is delayed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next